Saturday, June 25, 2022

Covid survivors face double risk of pulmonary blood clots, CDC warns

- Advertisement -
- Advertisement -

Survivors of Covid-19 are twice as likely to develop a blood clot in the lungs or a respiratory disease, according to a new study by the US Centers for Disease Control and Prevention (CDC).

The US government agency study released on Tuesday says adults between the ages of 18 and 64 have an increased risk of developing a pulmonary embolism — a clot in an artery in the lungs — or other respiratory conditions, such as a chronic cough or shortness of breath.

One in five Covid survivors in this age group and one in four survivors over the age of 65 have “experienced at least one incident condition that could be related to the previous infection,” it said.

With an increasing number of Covid-19 infections, many patients complain of persistent post-infection conditions or the onset of long-term symptoms that encompass a variety of health problems.

However, more research is needed to better understand who is more likely to experience ‘Long Covid’.

The study was based on analyzing medical records of people who had coronavirus infection between March 2020 and November 2021, and they were followed for 30 to 365 days after infection until the onset of health problems or the end of the period.

The data was then compared to others in a control group to determine the likelihood of these conditions.

The CDC study suggests that Covid prevention strategies, as well as routine assessment of post-Covid conditions in survivors, are critical to reducing incidence.

However, it had certain limitations as it did not take into account the subjects’ vaccination status.

Several studies in the past, including those by CDC, have indicated that Covid survivors may be at increased risk for health problems and need extensive follow-up care.

To date, over 80 million people in the United States have contracted Covid-19 and more than a million have died from the virus.

- Advertisement -
Latest news
- Advertisement -
Related news
- Advertisement -


Please enter your comment!
Please enter your name here